Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”

Leerink Partners, Piper Sandler and Stifel acted as joint bookrunning managers for this offering.

The Mintz capital markets team included William Hicks, John Rudy, Alok Choksi, Sam Silver, Gianna Nappi, Gretchen Goyette, and Chris Kinney.  Joanne Hawana provided regulatory advice; Serge Banini provided intellectual property advice; and Gregg Benson provided tax advice. Members of the Mintz team are based in the Boston, New York, Washington, DC, and San Diego offices.